Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 470-130-4 | CAS number: 697235-49-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Epidemiological data
Administrative data
- Endpoint:
- epidemiological data
- Type of information:
- other: human data
- Adequacy of study:
- supporting study
- Study period:
- 2009-09-28 to 2009-10-02
- Reliability:
- other: not rated acc.to Klimisch
- Rationale for reliability incl. deficiencies:
- other: Relevant
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
- Endpoint addressed:
- skin irritation / corrosion
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The capability of the test item to elicit visible skin damage was tested during a human patch test. 52 subjects participated in the study. The patch was applied to the skin of the back for 48 hours. After removal of the patch the skin site was graded 30 to 60, 24 and 48 hours after patch removal using a grading scale.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- -
- EC Number:
- 470-130-4
- EC Name:
- -
- Cas Number:
- 697235-49-7
- Molecular formula:
- Hill formula: C16H15NO4 CAS formula: C16H15NO4
- IUPAC Name:
- 2-((3-(4-Hydroxyphenyl)propanoylamino)benzoic acid
- Test material form:
- other: liquid
- Details on test material:
- - Physical state: colourless liquid
Constituent 1
Method
- Type of population:
- general
- Ethical approval:
- confirmed and informed consent free of coercion received
- Details on study design:
- HYPOTHESIS TESTED: to determine whether the test item (2%) is capable of eliciting visible skin damage during a forty-eight-hour period of contact.
METHOD OF DATA COLLECTION
- Type: Clinical tests
STUDY PERIOD: 2009-09-28 to 2009-10-02
STUDY POPULATION
- Selection criteria:
Inclusion criteria (satisfaction of all the following items was obligatory)
a) volunteer with phototype I, II, III
b) healthy subjects aged between 18 and 70 years.
c) males and females
d) provide signed Informed Consent
e) females of childbearing age must declare to use effective means of contraception for at least three months before beginning of the study and must maintain it throughout the study and for three months after its completion.
f) subjects whose medical examination confirmed their suitability for participation in the study.
g) according to the procedures of the Investigating laboratory, the wash-out period for each subject will be 1 month minimum time-lapse from the last participation in any clinical study involving a patch test on the back.
Exclusion criteria (any one of the following items was cause for rejection)
a) current use of immunosupressive drugs and/or an organ transplant;
b) current use of topical or systemic anti-inflammatory drugs for a defined medical condition; e.g. aspirin, ibuprofen, corticosteriods;
c) application within the last months of any-inflammatory drug to skin area to be used in testing;
d) insulin-dependant diabetes;
e) asthma suffering
f) currently receiving allergy injections, final injection within the last week, or experts to begin injections during the course of the study;
g) treatment for malignancy (of any kind) within the last six months;
h) immune deficiency or autoimmune disease;
i) lactating or known to be pregnant;
j) bilateral mastectomy, mastectomy within the last year; axillary lymph nodes (both arms) removed for any reason;
k) skin disorder affecting the test area which, in the supervisor's / designate's judgement, would interfere with grading / assessment of skin responses;
l) subjects with clinically significant dermographism or skin disorder that could compromise evaluation of skin reactions;
m) subjects with disorders which may be aggravated by the application of test materials (e.g. psoriasis, vitiligo);
n) intensive exposure to sunlight (natural or artificial) during 1 month preceding the study;
o) intensive treatment with systemic retinoids or topical retinoids applied on the test area less than 1 month before the current study;
p) vaccination during 3 weeks preceding the study or intention to be vaccinated during the course of the study;
q) a condition or medication which, in the investigator's judgement, makes the subject ineligible or places the subject at undue risk (if the potential subject is under the care of a physician, approval to participate may be sought from that physician, at the investigator's discretion and/or in accordance with regulatory requirements);
r) current participation in another clinical study of any kind;
s) unwillingness or inability to give informed consent or to otherwise comply with protocol requirements;
t) subjects who had been deprived of their freedom by administrative or legal decision or who are under guardianship;
u) subjects who cannot be contacted in case of emergency;
v) subjects with excessive skin reactivity to patch materials;
w) subjects with a history of side effects to cosmetics. - Exposure assessment:
- estimated
- Details on exposure:
- TEST SOLUTION
42 % of the test material in glycerin was used for application.
METHODOLOGY:
Occlusive patching devices were used to apply approximately 200 µL of the test item (2%) to the skin of the left upper back of each subject and to maintain it on its assigned site on each subject. These devices consisted of a 2 cm x 2 cm webril cotton square applied directly to the skin and secured in place with Hypafix® Tape.
The device was scheduled to be removed gently as circumstances permitted in the clinic by an experienced technician after forty-eight hours.
Daily regimen:
Day 1: skin of subjects were examined to ascertain that the skin was suitable for application. The occlusive patching device, as described above, was applied on its designated contact site and the skin around the device was marked. The subject was instructed to return at the same time the next day.
Day 2: the patch was examined to ascertain whether it was maintaining good contact on its assigned site. The subject was instructed to return at the same time the next day.
Day 3: the patch was removed. After a 30 to 60 minute waiting period, the contact site was examined and graded. The subject was instructed to return at the same time the next day.
Day 4: the contact site was examined and graded. The subject was instructed to return at the same time the next day.
Day 5: the contact site was examined and graded. The subject was dismissed from the study with instructions to notify the investigator immediately should the skin of the contact site manifest any change for the worse during the ensuing weeks.
Grading was performed in accordance with the following steps and scale.
1. Evaluation of erythema.
2. Evaluation of the presence of palpable elevated lesions.
3. Descriptions of other aspects concerning the test site.
Additional signs noted (when present) included vesicles, papules, bullae, desquamation, dryness, hyperpigmentation, soap effect, and spreading.
Grading scale:
No reaction = 0
Slight erythema, hardly visible, spotty or diffuse = 1
Moderate erythema, with well defined edges = 2
Severe erythema, possibly spreading beyond test site = 3
Oedema or papules with or without erythema = 4
Oedema and vesicles or bullae with or without erythema = 5
Caustic reaction (ulceration) = 6
PII index scale (PII range / irritancy level / irritancy category):
≤0.50 / essentially non-irritating / not a skin irritant
0.51 - 1.00 / virtually non-irritating / not a skin irritant
1.01 - 2.00 / minimally irritating / not a skin irritant
>2.00 moderately irritating / Primary skin irritant
Results and discussion
- Results:
- FINDINGS
- no complaint was volunteered by any of the subjects when they returned for inspection of the patches twenty-four hours after they were first applied.
- no adverse effect was detected on any of the 52 subjects (grade 0). - Confounding factors:
- no data
- Strengths and weaknesses:
- no data
Applicant's summary and conclusion
- Conclusions:
- None of the subjects showed adverse effects during the study (grade 0).
The absence of responses characterizes the tested mixture as one which does not possess clinically significant primary irritating propensities.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.